Abemaciclib combined with the estrogen inhibitor fulvestrant may significantly reduce the risk of disease progression and increase the objective response rate in women with metastatic breast cancer, according to the results of the MONARCH 2 study.
Two studies presented during the 2017 ASCO Annual Meeting provided additional evidence of the efficacy and safety of the CDK4/6 inhibitor ribociclib plus letrozole as a first-line treatment for ER-positive/HER2-negative advanced breast cancer.
Consensus guidelines on the minimal necessary margin width in the setting of breast-conserving surgery margins have great potential to increase standardization of practice and reduce morbidity and cost; however, we must be careful not to fall into the trap of practicing “cookbook medicine.”
A large study found that the individual surgeon and the institution exert greater influence on whether patients undergo mastectomy versus lumpectomy compared with all other clinical and demographic variables, except for tumor size and nodal status.
Results from the phase III ETNA study concluded there was no statistical difference in the pCR rate between neoadjuvant nab-paclitaxel and paclitaxel both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.
Extending aromatase inhibitor therapy beyond the standard 5 years out to 10 years for postmenopausal women with HR-positive early breast cancer significantly improves disease-free survival over placebo.
More than 2,000 patients are registered with the MBCP; 1,200 have consented to genetic sequencing. The MBCP has identified groups of traditionally underrepresented patients and patients with an ‘extraordinary response."
The latest evidence on overtreatment and the appropriate use of available therapies in breast cancer will be featured in the June 7 Education Session, “Less Is More: A Multidisciplinary Conversation on Treatment Options.”
New medications and longer survival rates have helped spur new ASCO guidelines on how clinicians can best treat their patients with different subsets of breast cancer. Compiled by co-chairs who worked with panels of experts from around the world, the guidelines encompass all aspects of cancer care.